Compounds, compositions and methods for protecting brain health in neurodegenerative disorders

Patent metadata

Field	Value
Publication number	US-9980980-B2
Application number	US-201414584581-A
Country	US
Kind code	B2
Filing date	Dec 29, 2014
Priority date	Jul 24, 2009
Publication date	May 29, 2018
Grant date	May 29, 2018

Abstract

Aspects of the invention relate to compounds, extracts and compositions thereof, and methods of using of the same, to treat neurodegenerative disorders and/or improve brain health. In certain embodiments, said compounds are pomegranate flavonoids.

First claim

We claim:

1. A method for improving memory function, comprising administering to a human in need thereof a therapeutically effective amount of punicalin or punicalagin, or a pharmaceutically acceptable salt of either of them, wherein the therapeutically effective amount is between about 100 mg per day and about 2,500 mg per day, wherein the human does not suffer from cancer.

2. The method of claim 1 , wherein the punicalin or punicalagin is administered as part of a nutraceutical composition, pharmaceutical composition, functional food, functional nutrition product, medical food, medical nutrition product, dietary supplement or botanical drug.

3. The method of claim 1 , wherein punicalin or a pharmaceutically acceptable salt thereof is administered.

4. The method of claim 1 , wherein punicalagin or a pharmaceutically acceptable salt thereof is administered.

5. The method of claim 1 , wherein long-term memory is improved.

6. The method of claim 1 , wherein short-term memory is improved.

7. The method of claim 3 , wherein long-term memory is improved.

8. The method of claim 3 , wherein short-term memory is improved.

9. The method of claim 4 , wherein long-term memory is improved.

10. The method of claim 4 , wherein short-term memory is improved.

11. The method of claim 1 , wherein the therapeutically effective amount is between about 250 mg per day and about 1,000 mg per day.

12. The method of claim 11 , wherein punicalin or a pharmaceutically acceptable salt thereof is administered.

13. The method of claim 11 , wherein punicalagin or a pharmaceutically acceptable salt thereof is administered.

14. The method of claim 11 , wherein long-term memory is improved.

15. The method of claim 11 , wherein short-term memory is improved.

16. The method of claim 12 , wherein long-term memory is improved.

17. The method of claim 12 , wherein short-term memory is improved.

18. The method of claim 13 , wherein long-term memory is improved.

19. The method of claim 13 , wherein short-term memory is improved.

20. A method for decreasing memory loss, comprising administering to a human in need thereof a therapeutically effective amount of punicalin nr punicalagin, or a pharmaceutically acceptable salt of either of them, wherein the therapeutically effective amount is between about 100 mg per day and about 2,500 mg per day, wherein the human does not suffer from cancer.

21. The method of claim 20 , wherein the punicalin or punicalagin is administered as part of a nutraceutical composition, pharmaceutical composition, functional food, functional nutrition product, medical food, medical nutrition product, dietary supplement or botanical drug.

22. The method of claim 20 , wherein punicalin or a pharmaceutically acceptable salt thereof is administered.

23. The method of claim 20 , wherein punicalagin or a pharmaceutically acceptable salt thereof is administered.

24. The method of claim 20 , wherein the memory loss is age-related.

25. The method of claim 22 , wherein the memory loss is age-related.

26. The method of claim 23 , wherein the memory loss is age-related.

27. The method of claim 20 , wherein the therapeutically effective amount is between about 250 mg per day and about 1,000 mg per day.

28. The method of claim 27 , wherein punicalin or a pharmaceutically acceptable salt thereof is administered.

29. The method of claim 27 , wherein punicalagin or a pharmaceutically acceptable salt thereof is administered.

30. The method of claim 27 , wherein the memory loss is age-related.

31. The method of claim 28 , wherein the memory loss is age-related.

32. The method of claim 29 , wherein the memory loss is age-related.

Assignees

• Amazentis Sa

Inventors

• Rinsch Christopher L
• Dupraz Philippe V

Classifications

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P3/02

  Nutrients, e.g. vitamins, minerals · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title